Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-05 pm EDT			5-day change	1st Jan Change
4.570 ^USD	-2.56%		+15.11%	-25.69%

Jun. 02	Myriad Genetics, Inc. Announces Appointment of Raj Jampa to Chief Technology Officer, Effective June 1, 2026	CI
May. 27	Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting	CI

Transcript : Myriad Genetics, Inc., Q1 2026 Earnings Call, May 05, 2026

Published on 05/05/2026 at 11:20 pm EDT - Modified on 05/15/2026 at 09:18 am EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good day and thank you for standing by. Welcome to the Myriad Genetics First Quarter 2026 Earnings Call. [Operator Instructions] Please be advised that

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Myriad Genetics, Inc.

Jun. 02	Myriad Genetics, Inc. Announces Appointment of Raj Jampa to Chief Technology Officer, Effective June 1, 2026	CI
May. 27	Myriad Genetics Highlights Data Demonstrating Broad Clinical Utility of Precise Mrd Assay At 2026 Asco Annual Meeting	CI
May. 26	Myriad Genetics to Launch Prolaris + AI Prostate Cancer Test	MT
May. 26	Myriad Genetics Launches Prolaris Plus AI Test Combining Genomics And Digital Pathology Artificial Intelligence	CI
May. 05	Myriad Genetics, Inc., Q1 2026 Earnings Call, May 05, 2026
May. 05	Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2026	CI
May. 05	Myriad Genetics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 29	MYR Q1 Earnings, Revenue Rise; Shares Gain After Hours	MT
Apr. 16	Qiagen N.V Showcases New Sample To Insight Solutions For Complex Oncology Applications	CI
Apr. 16	Myriad Genetics Announces Six Abstracts and Podium Presentations at AACR Annual Meeting	CI
Apr. 14	Myriad Genetics Secures Japanese Regulatory Approval For Prostate Cancer Diagnostic Test	MT
Apr. 14	Myriad Genetics Inc Expands Access For Mychoice Test To Prostate Cancer Patients In Japan	CI
Apr. 09	Myriad Genetics Announces New Data Presentations At Society of Gynecologic Oncology Annual Meeting	CI
Mar. 22	Myriad Genetics, Inc.(NasdaqGS:MYGN) dropped from S&P 600	CI
Mar. 22	Myriad Genetics, Inc.(NasdaqGS:MYGN) dropped from S&P Composite 1500	CI